{"id":"hsppc-96-or-oncophage","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (erythema, induration, pruritus)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Chills"}]},"_chembl":{"chemblId":"CHEMBL2108060","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HSPPC-96 (Oncophage) is an autologous therapeutic cancer vaccine composed of heat shock protein-96 (Hsp96) complexes bound to tumor-associated peptides isolated from each patient's surgically resected tumor. The vaccine works by presenting these tumor-specific antigens to the immune system, priming dendritic cells and T cells to recognize and attack remaining cancer cells expressing the same antigens. This personalized approach leverages the patient's own tumor biology to generate a targeted anti-tumor immune response.","oneSentence":"HSPPC-96 is a personalized cancer vaccine that uses heat shock protein-peptide complexes derived from a patient's own tumor to stimulate immune recognition and destruction of cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:46:09.202Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma (adjuvant setting)"},{"name":"Renal cell carcinoma (adjuvant setting)"}]},"trialDetails":[{"nctId":"NCT07077616","phase":"EARLY_PHASE1","title":"Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patients With Newly Diagnosed Glioma.","status":"RECRUITING","sponsor":"Biogenea Pharmaceuticals Ltd.","startDate":"2025-07-01","conditions":"Glioma","enrollment":29},{"nctId":"NCT03018288","phase":"PHASE2","title":"Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-09-21","conditions":"Glioblastoma","enrollment":90},{"nctId":"NCT02722512","phase":"PHASE1","title":"Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine","status":"TERMINATED","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2016-07","conditions":"Glioblastoma Multiforme, Astrocytoma, Grade III, Anaplastic Ependymoma","enrollment":10},{"nctId":"NCT00293423","phase":"PHASE1, PHASE2","title":"GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2005-11-18","conditions":"Brain and Central Nervous System Tumors","enrollment":96},{"nctId":"NCT00905060","phase":"PHASE2","title":"HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2009-06-29","conditions":"Brain and Central Nervous System Tumors","enrollment":70},{"nctId":"NCT02452281","phase":"PHASE1, PHASE2","title":"Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma","status":"WITHDRAWN","sponsor":"Rabih Said","startDate":"2015-12","conditions":"Melanoma","enrollment":""},{"nctId":"NCT00003025","phase":"PHASE1","title":"Vaccine Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1997-03","conditions":"Pancreatic Cancer","enrollment":16},{"nctId":"NCT00039000","phase":"PHASE3","title":"Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma","status":"COMPLETED","sponsor":"Agenus Inc.","startDate":"2002-03","conditions":"Malignant Melanoma","enrollment":350}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":40,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HSPPC-96 or Oncophage","genericName":"HSPPC-96 or Oncophage","companyName":"Agenus Inc.","companyId":"agenus-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HSPPC-96 is a personalized cancer vaccine that uses heat shock protein-peptide complexes derived from a patient's own tumor to stimulate immune recognition and destruction of cancer cells. Used for Metastatic melanoma (adjuvant setting), Renal cell carcinoma (adjuvant setting).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}